Presented by VisionWave: Discover how (NASDAQ: VWAV) is positioning itself inside some of the fastest-growing segments of the global defense technology market.

The market's biggest winner this morning isn't an AI darling or a household name. It's a company that coats metal, and it just delivered the kind of clean beat this tape is starving for, while an AI hardware player's global expansion took second place.

The losers all share one thing: they gave the market a reason to doubt. A failed late-stage drug trial is hammering a pharma giant, a guidance shortfall is dragging down a beloved denim brand, and Wall Street analysts are souring on both a software titan and a legacy automaker.

The defense industry is undergoing one of the biggest technological transformations in decades, and VisionWave Holdings, Inc. (NASDAQ: VWAV) is building directly into that shift. 

The company is developing a full-stack defense technology platform that integrates artificial intelligence, RF sensing, autonomous systems, and real-time analytics into a single operational architecture designed to deliver actionable intelligence faster than ever before. 

As governments increase spending on next-generation defense systems, technologies capable of detecting, analyzing, and responding to threats in real time are becoming mission-critical—and VWAV is working to establish itself in that rapidly expanding market. 

VWAV is building the kind of defense tech the world is actually going to use—AI, drones, and fast-response systems!

Recent developments suggest VWAV is moving aggressively to strengthen its position. The company has announced multiple patent initiatives, expanded its sensing capabilities, acquired valuable AI vision assets, and introduced technologies such as xCalibre™ and DeepWave RF™ that are designed to address real-world challenges across defense, homeland security, and advanced sensing applications. 

While still early-stage, VWAV is operating in sectors where innovation, urgency, and funding are increasingly converging, creating the type of environment where emerging technology companies can gain significant traction. 

VWAV is still small, but that means it could grow quickly if its technology takes off.

AZZ (AZZ): +8%

The metal coatings provider beat expectations on both the top and bottom lines for the latest quarter. It's not a flashy business, but in a tape punishing anything short of clean execution, quiet industrial consistency is getting paid.

Cerebras Systems (CBRS): +6%

The AI infrastructure company announced a major European expansion, with its first data center capacity on the continent coming online by year end and plans to scale to 2,000 megawatts across Europe by 2027. The AI compute buildout is officially going global, and the market is rewarding companies willing to plant flags early.

AstraZeneca (AZN): -8%

The biopharma giant tumbled after its heart disease drug Wainua failed to meet its target in a late-stage clinical trial. Late-stage failures are the most expensive kind, and this one is a reminder that binary pipeline risk applies even to the biggest names in the sector.

Salesforce (CRM): -5%

KeyBanc downgraded the software giant to sector weight, saying its research turned up little evidence of future upside. When an analyst's core argument is "we looked hard and couldn't find the catalyst," that lands harder than a typical valuation call.

Levi Strauss (LEVI): -3%

The denim giant beat second-quarter expectations on both the top and bottom lines, but its third-quarter earnings guidance came in below what the street was expecting. In this market, the quarter you just printed matters less than the one you're promising, and Levi's promise fell short.

Stellantis (STLA): -2%

The Jeep parent slid after JPMorgan downgraded it to neutral, with the analyst arguing the company needs another 14 months of work before its turnaround pays off. The market believes the recovery story; it just doesn't want to wait around for it.

The defense industry is undergoing one of the biggest technological transformations in decades, and VisionWave Holdings, Inc. (NASDAQ: VWAV) is building directly into that shift. 

The company is developing a full-stack defense technology platform that integrates artificial intelligence, RF sensing, autonomous systems, and real-time analytics into a single operational architecture designed to deliver actionable intelligence faster than ever before. 

As governments increase spending on next-generation defense systems, technologies capable of detecting, analyzing, and responding to threats in real time are becoming mission-critical—and VWAV is working to establish itself in that rapidly expanding market. 

VWAV is building the kind of defense tech the world is actually going to use—AI, drones, and fast-response systems!

Recent developments suggest VWAV is moving aggressively to strengthen its position. The company has announced multiple patent initiatives, expanded its sensing capabilities, acquired valuable AI vision assets, and introduced technologies such as xCalibre™ and DeepWave RF™ that are designed to address real-world challenges across defense, homeland security, and advanced sensing applications. 

While still early-stage, VWAV is operating in sectors where innovation, urgency, and funding are increasingly converging, creating the type of environment where emerging technology companies can gain significant traction. 

VWAV is still small, but that means it could grow quickly if its technology takes off.

Compass Pathways (CMPS)

Compass Pathways has been all over StockTwits this week, showing up in the platform's trending overnight lists and community polls as retail traders debate whether it becomes the first company to win FDA approval for a psilocybin-based depression therapy. The chatter picked up after the company's second Phase 3 trial confirmed durable results in treatment-resistant depression, and it hasn't cooled off.

The factual anchor: a rolling NDA submission with the FDA is already underway, with the final filing targeted for Q4 2026, a priority review voucher that could compress the review timeline, and a potential launch in the first half of 2027. Approval and DEA rescheduling both remain unresolved, so the next several months will determine whether this bet pays off or stalls out.

✌️That’s it for today.